Logo
x

Search

Subscribe Now

IASO Bio

IASO Bio Reports the US FDA’s IND Approval of Equecabtagene Autoleucel for Two New Autoimmune Diseases

IASO Bio Reports the US FDA’s IND Approval of Equecabtagene Autoleucel for Two New Autoimmune Diseases

  • August 12, 2024
IASO Bio and Innovent’s CT103A/ IBI326 Receive the US FDA’s Orphan Drug Designation for Multiple Myeloma

IASO Bio and Innovent’s CT103A/ IBI326 Receive the US FDA’s Orphan Drug Designation for Multiple Myeloma

  • February 14, 2022
PharmaShots Weekly Snapshots (May 30 – June 03, 2022)

    PharmaShots Weekly Snapshots (May 30 – June 03, 2022)

    • June 3, 2022
    IASO Biotherapeutics Reports the NMPA’s Acceptance of IND Application for Equecabtagene Autoleucel to Treat Neuromyelitis Optica Spectrum Disorder

      IASO Biotherapeutics Reports the NMPA’s Acceptance of IND Application for Equecabtagene Autoleucel to Treat Neuromyelitis Optica S...

      • May 30, 2022
      PharmaShots Weekly Snapshots (February 14-18, 2022)

        PharmaShots Weekly Snapshots (February 14-18, 2022)

        • February 18, 2022
        IASO Bio and Innovent’s CT103A/ IBI326 Receive the US FDA’s Orphan Drug Designation for Multiple Myeloma

          IASO Bio and Innovent’s CT103A/ IBI326 Receive the US FDA’s Orphan Drug Designation for Multiple Myeloma

          • February 14, 2022
          Image

          Incisive News in 3 Shots.

          Contact Us

          Our Information

          Follow Us

          Copyright © 2025 PharmaShots - All Rights Reserved.